Fifth PD-1, Zavicefta, Novel Psoriasis Ointment Among Latest China Approvals

Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.

Psoriatic Skin_1200x675
GLOBAL FIRST APPROVAL IN CHINA FOR NOVEL PSORIASIS AGENT • Source: Shutterstock

Four anti-PD-1 antibodies are already approved in China and the tally keeps going up.

Jiangsu Hengrui Medicine Co. Ltd. has become the latest developer to get approval for its product in the class,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from China

More from Asia